• In early May 2026, Becton, Dickinson and Company reported fiscal second-quarter sales of US$4,714 million but swung to a net loss of US$311 million, while reaffirming low single-digit plus GAAP revenue growth guidance for the full year and later appointing seasoned healthcare executive Peter Menziuso to lead BD Interventional from June 1.
• These results, coupled with leadership changes and an expanded infection-prevention partnership with Bactiguard on coated Foley catheters, highlight BD’s focus on execution, product innovation and long-term collaboration across its portfolio despite near-term profitability pressure and a voluntary recall affecting certain microbiology pouch systems.
• Now we will examine how BD’s solid operational growth and Menziuso’s appointment to BD Interventional may reshape the company’s investment narrative.

The latest GPUs need a type of rare earth metal called Dysprosium and there are only 28 companies in the world exploring or producing it. Find the list for free.

Becton Dickinson Investment Narrative Recap

To own BD today, you need to believe in its ability to turn solid top line growth, product innovation and recurring consumables demand into steadier earnings, even as one off items pull fiscal results into a net loss. The key short term catalyst is execution in BD Interventional and other higher growth franchises, while the most immediate risk is regulatory and quality pressure highlighted by the recent microbiology pouch recall; the latest news does not materially change those priorities.

Among the recent updates, the restated long term agreement with Bactiguard on coated Foley catheters looks especially relevant, because it deepens BD’s presence in infection prevention, a focus area singled out on the latest earnings call as a source of operational growth. If BD can keep scaling these kinds of specialized, clinically oriented products while stabilizing manufacturing and quality performance, it supports the case that current margin pressure is more cyclical than structural.

Yet investors should also weigh how the ongoing recall and quality scrutiny could affect BD’s ability to sustain these growth efforts and...

Becton Dickinson's narrative projects $20.8 billion revenue and $2.2 billion earnings by 2029. This implies revenue declining by 1.8% per year and an earnings increase of about $0.4 billion from $1.8 billion today.

Uncover how Becton Dickinson's forecasts yield a $192.31 fair value, a 31% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were assuming BD could reach about US$25.0 billion in revenue and US$3.3 billion in earnings by 2028, which is a far more upbeat story than consensus and could be tested by how recalls and leadership changes shape execution in BD Interventional and beyond.

Explore 3 other fair value estimates on Becton Dickinson - why the stock might be worth just $189.31!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Becton Dickinson research is our analysis highlighting 6 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Becton Dickinson research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Becton Dickinson's overall financial health at a glance.

Want Some Alternatives?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Outshine the giants: these 14 early-stage AI stocks could fund your retirement.
• Find 52 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.